Floatz logo

Mitoxantrone

Refractory Acute Leukemia of Ambiguous Lineage

Fred Hutchinson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Refractory Acute Leukemia of Ambiguous Lineage cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
SWOG Cancer Research Network
Phase 2B
METHOTREXATE
SWOG Cancer Research Network
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B

View all 50 →

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
myeloid neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →